Indian Institute of Technology
The University of Arizona
Ireena Bagai is a science advisor in the firm’s Litigation Department and a member of its Intellectual Property Group. She contributes to the firm's work in patent litigation, patent opinions and due diligence. Dr. Bagai joined Goodwin in 2016.
Dr. Bagai obtained her PhD in Biochemistry and Molecular Biophysics from University of Arizona. Her dissertation work focused on investigating the mechanism of drug export in multidrug resistant bacteria. Through her work, she elucidated the binding of antimicrobials to proteins that constitute the drug resistant system and showed protein-protein interactions to further play a role in mediating drug extrusion. She was awarded an “Outstanding Graduate Student Scholar ” award by the College of Science at University of Arizona for her extraordinary work during PhD. She was also a recipient of “Best Poster” awards at the Protein Society and Biophysical Society meetings respectively.
Prior to joining Goodwin, Dr. Bagai worked as a Post-doctoral associate at University of Michigan (UM) and Weill Cornell Medical College (WCMC) respectively. At UM, she conducted the structural characterization of an enzyme called hemoxygenase-2 (HO2) in varying redox states, in order to determine the structural differences that result in HO2’s differential affinity for heme. Dr. Bagai’s project at WCMC was a study of Alzheimer’s disease (AD). Specifically, her research involved designing and validating pharmacological chaperones to stabilize a protein that has been postulated to have a protective role in AD.
During her academic research career, Dr. Bagai has published several articles in prestigious peer-reviewed journals and has a book chapter to her credit.